Seres Therapeutics (NASDAQ:MCRB) Upgraded at Wall Street Zen

Posted by Stanley Muller on Aug 11th, 2026

Wall Street Zen upgraded shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) from a sell rating to a hold rating in a research note released on Saturday.

A number of other equities analysts have also recently issued reports on the stock. HC Wainwright assumed coverage on shares of Seres Therapeutics in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price objective on the stock. Zacks Research upgraded shares of Seres Therapeutics to a “hold” rating in a research report on Tuesday, June 23rd. Finally, Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Seres Therapeutics currently has a consensus rating of “Hold” and an average target price of $17.00.

Read Our Latest Report on MCRB

Seres Therapeutics Stock Up 2.7%

Shares of MCRB stock opened at $5.00 on Friday. The firm has a market cap of $49.70 million, a price-to-earnings ratio of -2.06 and a beta of 0.20. Seres Therapeutics has a 12 month low of $4.59 and a 12 month high of $29.98. The stock has a 50-day moving average price of $6.13 and a 200 day moving average price of $8.33.

Seres Therapeutics (NASDAQ:MCRB – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.18) by $2.65. The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.18 million. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. Sell-side analysts predict that Seres Therapeutics will post -4.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. grew its holdings in Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 89,995 shares during the period. Goldman Sachs Group Inc. raised its holdings in Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 21,679 shares during the period. Marshall Wace LLP acquired a new stake in Seres Therapeutics in the second quarter worth $1,016,000. Vanguard Group Inc. boosted its position in shares of Seres Therapeutics by 6.8% during the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after purchasing an additional 19,793 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Seres Therapeutics during the third quarter worth $557,000. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

(Get Free Report)

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.